Die Aktien von Illumina schmieren regelrecht ab, nachdem das Unternehmen seine Umsatz- und Gewinnprognose für das Gesamtjahr das zweite Quartal…
Die Aktien von Illumina schmieren regelrecht ab, nachdem das Unternehmen seine Umsatz- und Gewinnprognose für das Gesamtjahr das zweite Quartal…
Kulmbach (www.aktiencheck.de) - Illumina-Aktienanalyse von "Der Aktionär":
Fabian Strebin vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Illumina Inc. (ISIN: US4523271090,…
These are the stocks posting the largest moves in midday trading.…
Illumina expects flat growth in 2024, which lines up with other life sciences tools companies.…
Illumina Inc.’s stock ILMN fell 14% Friday to put it on track for its lowest close in 10 years, after…
Illumina shares slip after genetic testing group lowers profit guidance…
Illumina Inc (NASDAQ:ILMN) shares sank 11% in pre-market trading on Friday after the gene-testing company reduced its annual profit forecast…
Wynn Resorts, Illumina, Plug Power fall premarket; Apple rises…
Shares in Synaptics, Lions Gate Entertainment, Plug Power, Trade Desk, Unity Software and Illumina were all active in pre market…
…
(Reuters) – U.S. genetic testing Illumina on Thursday trimmed its annual profit forecast for the second straight quarter, hurt by…
…
Illumina cuts annual profit forecast for second straight quarter…
Shares of Illumina Inc. ILMN fell after hours on Thursday after the maker of DNA-sequencing technology cut its full-year sales…
Illumina plunges 8% on Q3 revenue miss & disappointing guidance…
…
Die Aktie von Illumina zählt heute zu den großen Verlierern an der Börse. Der Titel verliert deutlich an Wert. Zu…
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Nanopore Sequencing Market 2018-2028" report has been added to…
The Global Hereditary Testing Market Size was valued at USD 6.20 Billion in 2022 and the Worldwide Hereditary Testing Market…
…
TORONTO and NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- illumin (TSX: ILLM, OTC: ILLMF) (“illumin” or “Company”),…
Die Aktie von Illumina zählt heute zu den großen Verlierern an der Börse. Der Titel verbilligt sich am Mittwoch deutlich.…
Activist-investor Carl Icahn said his firm had sued current and former board directors at Illumina concerning the acquisition of gene-sequencing…
Activist Icahn sues Illumina board over Grail acquisition - FT…
…
Illumina to divest Grail within a year if it does not win challenge in EU court…
Illumina Inc. ILMN responded Friday to an order it received Thursday from the European Commission directing the company to…
Die Aktie von Illumina zählt am Donnerstag zu den großen Verlierern an der Börse. Das Wertpapier verliert deutlich an Wert.…
EU antitrust regulators order Illumina to sell Grail…
…
U.S. genetic testing company Illumina has been ordered by EU antitrust regulators to sell cancer test maker Grail after it…
Illumina ordered by EU antitrust regulators to sell Grail…
…
Illumina to divest Grail if it loses final court appeals in US or EU…
*VILLEROY/EZB: DIE ZINSSÄTZE SIND JETZT AUF DEM RICHTIGEN NIVEAUROG SW - Roche erzielt mit Augenmittel Vabysmo weiteren Behandlungserfolg ILLUMINA -…
EU regulators to order Illumina to sell Grail - Financial Times…
…
NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress…
London (www.aktiencheck.de) - Rating-Update:
Die HSBC stuft die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol: ILMN) unverändert…
Dublin, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The "Global Epigenomics Market Report and Forecast 2023-2031" report has been…
Prominent single-cell omics market players include 10x Genomics, Inc., Becton, Dickinson and Company (BD), CELLENION, PerkinElmer Inc., ANGLE plc, Illumina,…
…
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress…
Grund zur Freude haben Aktionäre von Illumina : Der Kurs der Aktie legt kräftig zu. Eine Steigerung um 4,12 Prozent…
Illuminas future is looking a bit dim at the moment....…
Minneapolis (www.aktiencheck.de) - Rating-Update:
Piper Sandler bestätigt das Rating "overweight" für die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Illuminas acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European…
...(Adds shares in paragraph 3)
Aug 11 (Reuters) - The U.S. Securities......…